Study summary
Starting sotatercept within a year of diagnosis prevented most early worsening
10.6%had clinical worsening, vs 36.9% with placebo
What was tested
Sotatercept against placebo, added to background therapy, for people diagnosed with pulmonary arterial hypertension within the previous year.
What they found
- Clinical worsening occurred in 10.6% vs 36.9% (hazard ratio 0.24).
- Hospitalization for worsening PAH was 1.9% vs 8.8%.
What it means
Supports adding sotatercept early, not only after other drugs fail.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.